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Intravenous (IV) iron and Erythropoiesis Stimulating Agents (ESAs) are recommended for anemia management in chronic kidney
disease (CKD). This retrospective cohort study analyzed utilization patterns of IV iron and ESA in patients over 18 years of
age admitted to University Health System Hospitals with a primary or secondary diagnosis of CKD between January 1, 2006
to December 31, 2008. A clustered binomial logistic regression using the GEE methodology was used to identify predictors of IV
iron utilization. Only 8% (n = 6678) of CKD patients on ESA therapy received IV iron supplementation in university hospitals.
Those receiving iron used significantly less amounts of ESAs. Patient demographics (age, race, primary payer), patient clinical
conditions (admission status, severity of illness, dialysis status), and physician specialty were identified as predictors of IV iron use
in CKD patients. Use of IV iron with ESAs was low despite recommendations from consensus guidelines. The low treatment rate
of IV iron represents a gap in treatment practices and signals an opportunity for healthcare improvement in CKD anemic patients.
1. Introduction
In the United States, Chronic kidney disease (CKD) aﬀects
approximately 26 million Americans and is the cause of
significant morbidity and mortality in 1 of 9 adults [1].
Anemia is a common comorbidity of CKD–prevalent in 47%
of patients who are not on dialysis [2]. Anemia of CKD
results from underproduction of endogenous erythropoietin
by the kidneys [3]. In patients with CKD not requiring
dialysis, untreated anemia increases cardiovascular risk,
hospitalization [4], all-cause mortality [5], and impaired
cognitive function [1], and diminishes health-related quality
of life [6] and exercise capacity [7, 8]. Heightened risk
for progression of kidney failure has also been linked to
untreated anemia of CKD. Thus, management of anemia in
CKD patients is essential [9–11].
Erythropoiesis-stimulating agents (ESAs), such as epo-
etin alfa (EPO) and darbepoetin, are used to treat anemia.
Use of ESAs substantially reduces the need for transfusions
and therefore are a first line of therapy for anemia of CKD
[12].
Despite their benefits, use of ESAs has inherent risks.
ESAs have been associated with increased risk of adverse
events, such as cardiovascular complications [13–16], hyper-
tension [17], and pure red cell aplasia [18]. The US Food and
Drug Administration (FDA) added a black box warning to
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the labeling of all epoetin and darbepoetin products advising
prescribers to adjust ESA dosing to maintain the lowest
hemoglobin level needed to avoid the need for red blood
cell transfusion [19]. In addition, the FDA recently required
all ESAs be a part of the Risk Evaluation and Mitigation
Strategies (REMS) program to ensure the safe use of these
drugs [20].
Adding iron to ESA regimens may reduce the dose of
ESAs required to target Hb levels and therefore reduce the
risk of adverse events. Iron supplementation replaces iron
lost through the process of erythropoiesis stimulated by
ESAs. Indeed, the Dialysis Patients Response to IV Iron with
Elevated Ferritin (DRIVE I and II) studies showed iron sup-
plementation with ESAs to be associated with higher Hb lev-
els and fewer serious adverse events [21, 22]. Consequently,
the National Kidney Foundation-Kidney Disease Outcomes
Quality Initiative (NKF-KDOQI) guidelines recommend
that supplemental iron be administered intravenously in
hemodialysis dependent CKD patients [23]. Guidelines also
recommend that nondialysis-dependent CKD patients and
peritoneal dialysis dependent CKD patients receive iron
orally or intravenously [23]. Ongoing administration of
parenteral iron preserves levels of hemoglobin and reduces
the requirement for administration of erythropoietin [15, 16,
24].
There have been no studies examining recent medication
utilization patterns of IV iron in CKD patients. A single
previous investigation reported trends in IV iron use among
US Medicare dialysis patients [25]. The study reported an
increase in the use of IV iron in ESRD patients from 1997
to 2002 with ferric gluconate and iron sucrose being the
predominant form of therapy [25]. This investigation uses
more recent data to quantify the rate and extent of IV iron
and ESA utilization in anemic CKD patients resulting from
the utilization of ESA with IV iron and without IV iron.
The primary objectives of this investigation are as
follows:
(1) to quantify the rate and extent of utilization of IV iron
and ESAs in anemic CKD patients across teaching
hospitals in the US,
(2) to identify predictors of IV iron and ESA use
among the domains of patient characteristics, clinical
conditions, physician characteristics, hospital charac-
teristics and treatment characteristics.
The authors hypothesize that IV iron supplementation
will lead to reduction in ESA use in anemic CKD patients
and that IV iron use is associated with patient character-
istics, clinical conditions, physician characteristics, hospital
characteristics, and treatment characteristics of anemic CKD
patients.
2. Methods
2.1. Data. Data for this research came from the Univer-
sity HealthSystem Consortium (UHC) hospital database,
a member-driven alliance of approximately 90% of the
nonprofit academic medical centers in the United States.
For this study, UHC’s Clinical Resource Manager (CRM)
database was used to gather data from hospital discharge
summaries and Uniform Billing-92 data. Inpatient records
from the database provided primary and secondary diag-
noses (in International Classification of Diseases, 9th Revision,
Clinical Modification [ICD-9-CM] format), inpatient pro-
cedure codes (in ICD-9-CM format), patient demographic
information (age, race, gender, primary and secondary
insurer), and hospital demographic information (bed size
and geographical location). The database also provided
admission and discharge dates as well as information on
comorbidities, severity of illness, and physician specialty.
2.2. Study Population. The data warehouse was electronically
queried for patients with Chronic Kidney Disease using ICD-
9-CM codes. Eligible patients were those who were admitted
to a UHC hospital with primary or secondary diagnoses of
CKD who received either IV iron or ESA or both at least
once during the period of January 1, 2006, and December
31, 2008.
2.3. Inclusion and Exclusion Criteria. Patients eligible for
inclusion had to be at least 18 years of age with primary or
secondary diagnosis of CKD. The patients in the treatment
cohort were required to have received ESA alone or ESA +
IV iron treatment during the study’s time period. Patients
with evidence of cancer diagnosis, chemotherapy or radio-
therapy, blood transfusion, severe gastrointestinal bleeding,
HIV/AIDS during the observation period were excluded to
avoid including patients receiving ESA or IV iron for reasons
other than anemia of CKD. Diagnoses and procedure codes
used for inclusion and exclusion are described in Tables 1 and
2. This study was approved by the Virginia Commonwealth
University institutional review board.
2.4. Statistical Analysis. Statistical analyses were performed
using the Statistical Analysis Software (SAS v. 9.2) and the
Predictive Analytical Software (PASW v. 17.0, previously
SPSS) statistical software. A two-sided alpha of 0.05 was
considered significant.
For description of IV iron and ESA use, percentages
and chi-square values were calculated for the study sample
and subcategories. To assess the prevalence rate of usage of
ESA and IV iron from 2006 to 2008, a trend evaluation was
performed for both the drugs. Diﬀerences between the study
groups were calculated using t-tests, statistical significance
set at P < 0.05. The days of therapy (DOTs) for ESA and
IV iron therapy administered to individual patients were
determined. The mean duration of therapy for each drug
was calculated. The aggregate of drug use in each hospital for
each year was expressed as DOTs per 100 patient-days (PDs).
For example, if a patient received a single dose of a drug (ESA
or IV iron) on a given day, whether or not multiple doses are
usually administered, it was registered as 1 DOT. If a patient
received more than 1 ESA drug (epoetin or darbepoetin) on
the same day, it was counted as 1 DOT for ESA therapy.
Days of hospitalization for each patient at each hospital were
summed to provide total patient-days (PDs).
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Table 1: Diagnoses codes (ICD-9-CM) and procedure codes used to identify Chronic Kidney Disease patients (inclusion criteria).
Diagnoses and procedure codes for inclusion criteria
Diagnoses codes
Description ICD-9-CM Codes
Chronic renal failure 585.1–585.6, 585.9
Renal failure, unspecified 586
Renal sclerosis, unspecified 587
Hypertensive renal disease 403.00–403.9
Hypertensive heart and renal disease 404.00–404.9
Nephrotic syndrome 581.0–581.9
Chronic glomerulonephritis 582.0–582.9
Nephritis (NOS as acute or chronic) 583.0–583.9
Chronic pyelonephritis (without lesion of renal medullary necrosis) 590.00
Chronic pyelonephritis (with lesion of renal medullary necrosis) 590.01
Renal dialysis status V45.1
Fitting or adjustment to dialysis catheter V56.1-V56.2
Adequacy testing for hemodialysis or peritoneal dialysis V56.3, V56.31, V56.32
Encounter for dialysis and dialysis catheter care V56.0, V56.8
Anemia of Chronic kidney disease 285.21
Procedure codes
Hemodialysis 39.95
Peritoneal dialysis 54.98
Table 2: Diagnoses codes (ICD-9-CM) and procedure codes used to identify Chronic Kidney Disease patients (exclusion criteria).
Diagnoses and procedure codes for exclusion criteria
Diagnoses codes
Description ICD-9-CM Codes
Neoplasms 140.00–239.00
Blood transfusion V58.2
Kidney/other organ transplant 996.8, E878.0, V42
Gastrointestinal bleeding 569.3, 578.9, 626, 627
HIV/AIDS 042, V08, 795.71
Procedure codes
Chemotherapy 00.10, 99.85, 99.25, 92.28, 99.28
Radiation therapy 14.26, 92.41, 92.25, 92.21, 92.22, 0.18, 14.27, 92.26
Blood transfusion 99.03, 38.92, 38.94, 99.02
Kidney/organ transplant 00.91–00.93
Gastrointestinal bleeding 44.43, 44.44
A clustered binomial logistic regression model using the
GEE methodology was used to identify the predictors of
IV iron use. The dependent variable was drug use, and
the independent variables to be included in the model
were (1) patient characteristics (age, race, gender, length
of stay, primary payer), (2) patient clinical conditions
(admission status, severity of illness, discharge status, dialysis
status), (3) physician characteristics (physician specialty), (4)
hospital characteristics (total hospital costs). Comparisons
were considered statistically significant at P < 0.05. A
goodness of fit test (QIC and QICC) was performed to
evaluate how well the model fits the observations [26].
The goodness of fit test helped determine which of the
correlation structures was more appropriate and the best
subset of predictors. A Huber-White sandwich estimator
(robust estimator) was used to ensure that the variances were
robust [27]. Specifically, robust variances are important as
they provide accurate assessments of the sample-to-sample
variability of the parameter estimates even if the model is
misspecified.
3. Results
3.1. Study Population. Demographic, clinical, and treatment
characteristics for the study sample for the categorical
variables are described in Tables 3, 4, and 5. The typical
patient in the total sample was a black male over 50 years
of age with an emergency admission paid for by Medicare.
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Table 3: Demographic characteristics of the study sample.
Variable
ESA + IV Iron ESA alone Total
n = 6678 n = 76269 N = 82947
Demographic characteristics
n (%) n (%) N (%)
Age group (years)∗
18–30 369 (5.53) 4728 (6.20) 5097 (6.14)
31–50 1476 (22.10) 19349 (25.37) 20825 (25.11)
51–64 2074 (31.06) 24546 (32.18) 26620 (32.09)
≥65 2759 (41.31) 27647 (36.25) 30406 (36.66)
Race∗
White 3348 (50.13) 30504 (40) 33852 (40.81)
Black 2299 (34.43) 32010 (41.97) 34310 (41.36)
Hispanic 514 (7.70) 7742 (10.15) 8256 (9.95)
Other 517 (7.74) 6013 (7.88) 6530 (7.87)
Gender
Male 3615 (54.13) 39940 (52.37) 43555 (52.51)
Female 3063 (45.87) 36330 (47.63) 39393 (47.49)
Primary payer∗
Commercial/Private payer 1157 (17.33) 11092 (14.54) 12249 (14.77)
Medicare 4588 (68.70) 53834 (70.58) 58422 (70.43)
Medicaid 710 (10.63) 9026 (11.83) 9736 (11.74)
Self-pay 97 (1.45) 924 (1.21) 1021 (1.23)
Other 126 (1.89) 1394 (1.83) 1520 (1.83)
∗Diﬀerences between the study groups were statistically significance at P < 0.05.
The average patient was not on dialysis, had an illness status
rated as “major,” and was discharged or transferred alive. The
typical patient was treated by an internal medicine physician,
in a hospital of more than 600 beds, andmore likely to receive
epoetin as an ESA.
Of the 82,947 patients receiving ESAs, only 6,678 (8%)
received IV iron. Univariate chi-square tests indicated signif-
icant diﬀerences for all categories of demographic, clinical,
and treatment characteristics although some variables had
greater practical diﬀerences than others. One diﬀerence was
the age related-impact of IV iron use which increased with
age. Another diﬀerence was race where whites were more
likely than other racial categories to receive iron with ESAs.
Iron supplementation was more likely with epoetin than
darbepoetin, and iron sucrose was used much more often
with ESAs than iron dextran. Univariate statistical diﬀerences
in gender, primary payer, admission status, severity of illness,
discharge status, dialysis status, physician specialty, bed size,
and geographical region were present although they varied
by a few percentage points.
3.2. Trends for IV Iron and ESA Use and Days of Therapy.
Figure 1 displays the usage trends for IV iron and ESA
therapy in CKD patients over the study period. ESA use
increased from 2006 to 2007 and then decreased after the
last quarter of 2007 to 2008. In contrast, the use of IV
iron therapy in CKD patients on ESA showed a small but
steady increase over the two-year period. Comparing the two
therapeutic groups (ESA + IV iron and ESA alone), fewer
patients used IV iron along with ESA from 2006 to the second
quarter of 2007. There was a notable increase in the number
of patients using IV iron along with ESA as compared to ESA
alone from the third quarter of 2007 to 2008.
Of the individuals on IV iron, 85% (n = 5,678) received
iron sucrose and the remaining 15% (n = 1,000) received
iron dextran. Average IV iron use in CKD patients increased
sharply from 2006 to 2008 (Table 6), although it still
remained a small fraction of all CKD patients.
The days of therapy (DOTs) for ESA and IV iron therapy
administered to individual patients was determined. The
mean duration of therapy for each drug was calculated.
The aggregate of drug use for each year was expressed
as DOTs per 100 patient-days (PDs). Table 7 lists the
mean DOTs/100 PDs for IV iron and ESA therapy. The
mean (±SD) ESA DOTs/100 PDs was 12.36 ± 21.92 in
the ESA group and 8.66 ± 20.28 in the IV iron group.
t-test results showed a statistically significant mean dif-
ference of 3.7 [(95% CI = 3.15, 4.24), SE = 0.278,
P < 0.001].
Figure 2 shows change in the mean ESA DOTs/100 PDs
with each quarter of drug use from 2006–2008. There is a
significant increase in themean ESA use in the first quarter of
2006 (P = 0.03). Notice the significant (P = 0.005) decrease
in the use of ESA from the second quarter of 2006 to the
third quarter of 2007. A substantial drop in the mean use
of ESA occurred from the third quarter of 2006 to the first
quarter of 2008 (P < 0.001). Figure 3 shows the change in the
mean IV Iron DOTs/100PDs with each quarter of drug use
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Table 4: Clinical characteristics of the study sample.
Variable
ESA + IV Iron ESA alone Total
n = 6678 n = 76269 N = 82947
Clinical characteristics
Admission status∗
Emergency 4130 (61.84) 44360 (58.16) 48490 (58.46)
Urgent 1436 (21.50) 20015 (26.24) 21451 (25.86)
Elective 1017 (15.23) 10636 (13.95) 11653 (14.05)
Other 95 (1.42) 1259 (1.65) 1354 (1.63)
Severity of illness∗
Moderate 817 (12.32) 10205 (13.38) 11022 (13.29)
Major 3859 (57.79) 41673 (54.64) 45532 (54.89)
Extreme 2002 (29.98) 24392 (31.98) 26394 (31.82)
Discharge status∗
Discharged/Transferred alive 6440 (96.44) 72782 (95.43) 79222 (95.51)
Expired 236 (3.53) 3461 (4.54) 3697 (4.46)
Other 2 (0.03) 26 (0.03) 28 (0.03)
Dialysis status∗
On dialysis 1776 (26.59) 23546 (30.87) 25322 (30.53)
Not on dialysis 4902 (73.41) 52724 (69.13) 57626 (69.47)
Physician specialty∗
Internal medicine 2182 (32.67) 25652 (33.63) 27834 (33.56)
Nephrology 1319 (19.75) 12793 (16.77) 14112 (17.01)
Cardiology 750 (11.23) 8141 (10.67) 8891 (10.72)
Transplant 273 (4.09) 3696 (4.85) 3969 (4.78)
Pulmonary/Critical care 196 (2.94) 2635 (3.45) 2831 (3.41)
Hospitalist 320 (4.79) 3391 (4.45) 3711 (4.47)
Surgery 823 (12.32) 9260 (12.14) 10083 (12.16)
Bed size∗
1–399 1728 (25.88) 12309 (16.14) 14037 (16.92)
400–599 1281 (19.18) 22099 (28.98) 23380 (28.19)
600–799 2005 (30.02) 25584 (33.54) 27589 (33.26)
800 or more 1664 (24.92) 16278 (21.34) 17942 (21.63)
Geographical region∗
Midwest 2416 (36.18) 17498 (22.94) 19914 (24.01)
Northeast 1826 (27.34) 17045 (22.35) 18871 (22.75)
Southeast 848 (12.70) 17264 (22.64) 18112 (21.84)
Southwest 456 (6.83) 10879 (14.26) 11335 (13.67)
West 1132 (16.95) 13583 (17.81) 14715 (17.74)
∗
Diﬀerences between the study groups were statistically significance at P < 0.05.
Table 5: Treatment characteristics of the study sample.
Variable
ESA + IV Iron ESA alone Total
n = 6678 n = 76269 N = 82947
Treatment characteristics
ESA type∗
Epoetin 3428 (51.3) 44106 (57.8) 47534 (57.3)
Darbepoetin 2082 (31.2) 32163 (42.2) 34245 (41.3)
Unknown 1168 (17.5) 0 (0) 1168 (1.4)
IV iron type
Iron sucrose 5678 (85) NA NA
Iron dextran 1000 (15)
∗
Diﬀerences between the study groups were statistically significance at P < 0.05.
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Table 6: Annual percentages of chronic kidney disease patients treated with IV iron.
2006 2007 2008
Hemodialysis
Total number of patients 395 544 779
Iron sucrose (%) 359 (91) 514 (94) 718 (92)
Iron dextran (%) 36 (9) 30 (6) 61 (8)
Peritoneal dialysis
Total number of patients 17 18 23
Iron sucrose (%) 10 (41) 16 (89) 19 (83)
Iron dextran (%) 7 (59) 2 (11) 4 (17)
Not on dialysis
Total number of patients 1197 1516 2189
Iron sucrose (%) 923 (77) 1263 (83) 1856 (85)
Iron dextran (%) 274 (23) 253 (17) 333 (15)
Table 7: Mean days of therapy/100 patient days by drug group.
IV Iron +ESA therapy ESA therapy alone
Variable
Mean SD Mean SD P-value
ESA DOTs/100 PDs 8.66 20.28 12.36 21.92 <0.001
IV Iron DOTs/100 PDs 30.41 28.20 NA NA NA
IV: Intravenous.
ESA: Erythropoiesis stimulating agents.
DOTs: Days of therapy.
PDs: Patient days.
Percentage of CKD patients (N = 82.947) receiving ESA and 
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Figure 1: Quarterly percentages of the study population receiving
ESA alone and ESA + IV iron from 2006–2008.
from 2006–2008. Note the significant increase of IV iron use
from the first quarter of 2007 to the second quarter of 2008
(P < 0.001).
3.3. Predictors of IV Iron Use. Older adults (≥65 years)
were 1.246 times more likely to be prescribed IV iron for
anemia of CKD compared to young adults in the age range
of 18–30 years [95% CI (1.108, 1.402), P < 0.001]. Race
was found to be a strong predictor of drug use in the
anemic CKD population. African Americans and Hispanics
were 0.685 [95% CI (0.647, 0.726) P < 0.001] times and
0.627 [95% CI (0.567, 0.695) P < 0.00] times as likely
to receive IV iron compared to the White population on
ESA therapy. Patients covered under the Medicaid, any
commercial/private insurance or who paid out of pocket for
insurance were 1.141 [95% CI (1.044, 1.247) P = 0.003],
1.265 [95% CI (1.178, 1.360) P < 0.001],and 1.451 [95%
CI (1.171, 1.798) P = 0.001] times more likely to receive
IV iron therapy as compared to patients covered under
Medicare.
Patient admission status, severity of illness, dialysis
status, and patient length of stay were strong predictors of
drug use in the anemic CKD population. Patients admitted
to the hospital as emergency and elective cases were 1.34
[95%CI (1.256, 1.430) P < 0.001] times and 1.307 [95%CI
(1.202, 1.421) P < 0.001] times more likely to be prescribed
IV iron as compared to patients admitted to the hospital as
urgent cases. “Extremely” sick CKD patients were less likely
to receive IV iron as compared to “moderately” sick patients.
CKD patients not on dialysis were 0.851 [95% CI (0.8, 0.907)
P < 0.001] times as likely to receive IV iron as compared to
CKD patients on dialysis.
Nephrologists were 1.216 [95% CI (1.131, 1.308) P <
0.001] times more likely to prescribe IV iron to CKD patients
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ESA: erythropoiesis stimulating agents
DOTs: days of therapy
PDs: patient days
CI: confidence interval
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Figure 2: Mean ESA DOTs/100 PDs use (with 95% CI) from 2006–
2008 (by each quarter).
already on ESA therapy, compared to internal medicine phys-
icians. Transplant specialists and surgeons were 0.772 [95%
CI (0.664, 0.898) P = 0.001] and 0.912 [95% CI (0.836,
0.995) P = 0.03] times as likely to prescribe IV iron to CKD
patients compared to internal medicine physicians.
4. Discussion
In this inquiry, we described the utilization of IV iron
and ESA in anemic CKD patients. Of the 82,947 CKD
patients on ESA therapy, only 8% (n = 6,678) were on IV
iron supplementation. Of those 6678 patients on IV iron,
91% were prescribed iron sucrose, and the rest received
iron dextran. Almost 30% of the CKD population was on
hemodialysis (n = 25,322).
Previous investigations report varying prevalences of IV
iron usage. Bailie et al. found IV iron being prescribed to
20% of the patients with anemia of CKD [28]. This study
included patients from four academic nephrology centers
where prescribing physicians might have been more familiar
with CKD treatment guidelines. Rasu et al. reported only 3%
of CKD patients with anemia in outpatient settings of the
US were prescribed IV iron [29]. Reasons for low prevalence
of IV iron use in this investigation are unclear, particularly
because the NKF-KDOQI clinical practice guidelines for
anemia, which are repeatedly published since 1997, make
firm recommendations for optimal use of IV iron supple-
mentation in hemodialysis patients.
Concerns regarding long-term safety of IV iron may have
had a role in such low prevalence of use. These concerns arise
from the known eﬀect of iron as a growth factor of bacteria
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Figure 3: Mean IV Iron DOTs/100 PDs use (with 95% CI) from
2006–2008 (by each quarter).
[30–32], its suspected inhibition of neutrophil function [33],
and increased oxidative stress leading to atheromatous [34–
36] change as well as anaphylactic and other adverse events
associated with the use of IV iron. No large prospective
clinical trials have investigated the relationship between iron
dosing and infectious morbidity or mortality. Observation
studies by Feldman et al. [37, 38] examined the eﬀect of
IV iron on mortality and hospitalization. One study of
32,566 hemodialysis patients during 1996 and 1997 found
no significant association between cumulative iron dose and
all-cause mortality. Results of this report provide cautious
support for the safe use of cumulative iron doses greater than
1000mg during 6 months, if needed to maintain target Hb
levels in hemodialysis patients. However, some cliniciansmay
still be reluctant to use iron because of lingering concerns
about iron toxicity issues.
The data indicates that ESA use is decreasing and IV
iron use is increasing, although the rate of IV iron use is
still quite low. Several events could explain these trends. The
decrease in ESA use is likely due to safety concerns with
ESA use which have resulted in a black-box warning on all
ESA products instructing prescribers to use the lowest ESA
dose that gradually increases hemoglobin concentrations to
the lowest level suﬃcient to avoid the need for red blood
cell transfusion [19]. Also, the FDA recently stated that all
ESAs prescribed must be a part of the Risk Evaluation and
Mitigation Strategies (REMS) program to ensure the safe use
of these drugs [20].
The increase in iron use is likely due to the National
Kidney Foundation-Dialysis Outcomes Quality Initiative
(NKF-DOQI) of 2006 which revised the clinical practice
8 Anemia
guidelines for anemia of CKD. The NKF-KDOQI guidelines
recommend that a CKD patient’s hemoglobin (Hb) be
checked annually regardless of the cause or state of their
CKD [1]. In addition, the guidelines firmly recommend iron
supplementation in order to maintain adequate iron indices
that is, transferrin saturation (TSAT) and serum ferritin
levels and Hb levels.
Despite the NKF-DOQI guidelines, only 8% (n = 6678)
of CKD patients receiving ESAs got IV iron. Of that number,
most were prescribed iron sucrose. Only 9% of patients
received iron dextran—most likely because of its known risk
of causing anaphylactoid and other life-threatening adverse
reactions. No evidence of sodium ferric gluconate use was
found in this data.
The days of therapy (DOTs) for ESA and IV iron
therapy administered to individual patients was determined
to quantify utilization of IV iron and ESA use, relative to the
use of ESA alone. Although the defined daily dose (DDD)
method is recommended by the World Health Organization
to estimate drug use, important deficiencies of the defined
daily dose method compared with direct measure of the
DOTs have recently been reported [39–42]. Specifically, the
defined daily dose method is intended to estimate the DOTs
from the quantity of drug purchased by the hospital [42].
In most countries, purchase data are more readily available
than measures of the DOTs. Electronic capture of pharmacy
dispensing and administration data now makes it feasible to
measure DOTs directly. Moreover, in the UHC data, diﬀerent
hospitals have diﬀerent measurement of units (vial, mg, mcg,
mL, units, etc.), making it diﬃcult to quantify the dose
of ESA or IV iron therapy using the DDD methodology.
DDD methods will underestimate drug exposure when
the administered daily dose is reduced for a patient with
impaired bodily function or sudden adverse events. Also,
if the administered daily dosage diﬀers significantly from
the WHO-approved DDD, then DDD methodology will not
provide an accurate assessment of the number of days of
therapy. Days of therapy (DOTs) are the most common
alternative measure of drug consumption in hospitals.
A clustered binomial logistic regression using generalized
estimating equations (GEEs) was used to identify potential
predictors of IV iron use in anemic CKD patients. Older
adults (≥65 years) were significantly more likely to be
prescribed IV iron for anemia of CKD compared to young
adults in the age range of 18–30 years. This finding is con-
sistent with the literature demonstrating a high prevalence
of IV iron use among older adults [28]. Race was found
to be a strong predictor of drug use in the anemic CKD
population. Blacks andHispanics were significantly less likely
to receive IV iron compared to the White population on ESA
therapy. This finding is consistent with the current literature
[28, 43] and can be associated to the socioeconomic status
of these races. Patients covered under the Medicaid, any
commercial/private insurance or who paid out of pocket for
insurance, were significantly more likely to receive IV iron
therapy as compared to patients covered under Medicare.
This finding is debatable considering the ambiguity in
Medicare coverage decisions for ESRD and predialysis CKD
patients. Dialysis patients, regardless of age, have been
entitled to Medicare coverage since 1972 [44]. As a result of
widespread coverage, Medicare serves as primary insurance
for the majority of ESRD patients after the initiation of
dialysis. Most dialysis patients below the age of 65, however,
are not eligible for Medicare benefits until the fourth month
after initiating dialysis. Medicare does not cover any costs of
treatment during these first three months of dialysis unless
the patient already has primary Medicare coverage because
of age or disability. The private health plan is the only payer
for the first three months of dialysis. When a patient becomes
eligible for Medicare due to ESRD in the fourth month of
dialysis, there is a 30-month “coordination period” when
the health plan serves as the primary payer for health care
services and Medicare becomes the secondary payer. At the
end of this 30 month period, Medicare pays for all Medicare
covered services as a primary payer, and the health plan
becomes the secondary payer [44]. Only 31% of the sample
CKD population (N = 82,947) was on dialysis, while the
majority (>60%) of patients were predialysis CKD patients
and in the age range of less than 65 years who may not be
covered by Medicare as their primary payer.
Patients admitted to the hospital as emergency and
elective cases were significantly more likely to be prescribed
IV iron as compared to patients admitted to the hospital as
urgent cases. “Extremely” sick CKD patients were less likely
to receive IV iron as compared to “moderately” sick patients.
This finding can be explained by the concerns physicians may
have regarding the use of IV iron in terminally ill patients
and toxicity issues with IV iron. These concerns arise from
the known eﬀect of iron as a growth factor of bacteria [30–
32], its suspected inhibition of neutrophil function [33],
and increased oxidative stress leading to atheromatous [34–
36] change as well as anaphylactic and other adverse events
associated with the use of IV iron. CKD patients on dialysis
were less likely to receive IV iron as compared to CKD
patients not on dialysis. However, this finding is unusual
considering that IV iron is highly recommended to CKD
patients on dialysis.
With regards to physician specialty, nephrologists were
more likely to prescribe IV iron to CKD patients already
on ESA therapy compared to internal medicine physicians;
whereas transplant specialists and surgeons were significantly
less likely to prescribe IV iron to these patients. This finding
is consistent with our hypothesis. Recent emphasis has called
for early referral of CKD patients to nephrologists, since
this approach has been demonstrated to improve patient
outcomes and result in earlier preparation for an initiation
of dialysis and prescribe the appropriate therapy as needed
[45].
Inevitably, there were limitations to this investigation.
The first limitation is the diﬀerence in hospitals with
respect to anemia and CKD management policies and
formularies/protocols that cause variations in the utilization
patterns. However, hospital level factors were used in an
attempt to control for interhospital variability while assessing
utilization. Also, a clustered analysis using the GEE method-
ology was used to account for nesting of patients within
hospitals to control for erroneous inferences of associations
between independent variables and drug use. In the clustered
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models, we put a restriction that patients within a hospital
are nested and correlated when compared with patients
between diﬀerent hospitals.
Adjusting for underlying severity of illness was diﬃcult
in this investigation, because there is currently no well-
validated severity of illness score for CKD. Previous investi-
gations have used a variety of techniques including the Stoke
Comorbidity Grade (SCG) [46], the Khan index [47], the
Davies index [48], and the Charlson comorbidity index [49].
Unlike other indices, the Davies index does not include age,
because it was specifically designed to be used in conjunction
with age as an independent covariate. Other comorbidity
indices used in studies on ESRD patients assigned diﬀerent
weights to diﬀerent comorbidities, such as the Khan or the
Charlson index, with the weights based on the impact of
comorbid diseases on survival [50]. However, the impact
of comorbid diseases on survival may be diﬀerent from
their impact on health status and resource use [50]. This
investigation used the All Patient Refined Diagnosis Related
Groups (APR-DRGss) classification system to adjust for
severity of underlying illness [51]. The APR-DRG system
is an enhancement of the DRG structure and is a good
predictor of drug utilization, hospital costs, and resource use
[52, 53].
This investigation does not assess the appropriateness
of each the patient’s iron supplementation therapy. It is
possible that each choice not to supplement ESA use with
IV iron was rational and evidence based. However, IV iron
supplementation has been linked to better patient outcomes
for CKD anemia [22].
The patient population in this study may not represent
all CKD patients in the nation. The University HealthSystem
Consortium (UHC) database used for this study is derived
from a group of university teaching hospitals providing
tertiary care. University hospitals are diﬀerent from other
hospitals because they typically perform more complex
procedures, have higher costs, and result in longer patient
length-of-stays than community hospitals.[54] Therefore,
the results of this study may not be directly extrapolated to
the general hospital community of the USA.
Finally, this study faces the same limitation seen in any
exploration of archived inpatient hospital data. Inaccurate
coding or missing data may introduce bias in the results.
Also, the database does not contain data that might be better
predictors of prescribing. We were unable to assess physi-
cians’ prescribing intent or their knowledge of recommended
guidelines. In addition, we could not assess pharmaceutical
industry influence or laboratory values such as hemoglobin,
transferrin saturation, serum ferritin, and other iron indices
which may be possible predictors of IV iron use in anemic
CKD patients.
5. Conclusion
This inquiry describes the utilization of IV iron and ESA
in anemic CKD patients, with a focus on understanding
predictors of drug use. Data collected from 62 teaching
hospitals between 2006 and 2008 showed an increasing trend
in the use of IV iron in anemic CKD patients already on
ESA therapy. Use of IV iron supplementation was associated
with a significant decrease in the duration of therapy of ESA.
Despite this positive finding for supplementing ESA admin-
istration with IV iron, only 8% of CKD patients receiving
ESAs also received IV iron. Patient demographics (age, race,
primary payer), patient clinical conditions (admission status,
severity of illness, dialysis status), and physician specialty
were identified as predictors of IV iron use in CKD patients.
Use rates of IV iron in this population suggest that
anemia management therapies may be underutilized in
CKD anemic patients in spite of emphasis on the use of
IV iron in the consensus guidelines. The low treatment
rate represents a gap in treatment practices and signals
an opportunity for healthcare improvement. Pathologic
factors, physician practice patterns, pharmaceutical industry
influence aﬀecting rates of IV iron use in anemia of CKD,
along with patient-centered clinical and economic outcomes
of such treatment merit further research.
References
[1] National Kidney Foundation, “KDOQI clinical practice guide-
lines clinical practice recommendations for anemia in chronic
kidney disease,” American Journal of Kidney Disease, vol. 50,
pp. 471–530, 2007.
[2] W. McClellan, S. L. Aronoﬀ, W. K. Bolton et al., “The
prevalence of anemia in patients with chronic kidney disease,”
CurrentMedical Research andOpinion, vol. 20, no. 9, pp. 1501–
1510, 2004.
[3] J. D. Jensen, J. K. Madsen, L. W. Jensen, and E. B. Pedersen,
“Reduced production, absorption, and elimination of erythro-
poietin in uremia compared with healthy volunteers,” Journal
of the American Society of Nephrology, vol. 5, no. 2, pp. 177–
185, 1994.
[4] S. S. Khan, W. H. Kazmi, R. Abichandani, H. Tighiouart, B.
J. Pereira, and A. T. Kausz, “Health care utilization among
patients with chronic kidney disease,” Kidney International,
vol. 62, no. 1, pp. 229–236, 2002.
[5] J. Fink, S. Blahut, M. Reddy, and P. Light, “Use of erythro-
poietin before the initiation of dialysis and its impact on
mortality,” American Journal of Kidney Diseases, vol. 37, no. 2,
pp. 348–355, 2001.
[6] D. A. Revicki, R. E. Brown, D. H. Feeny et al., “Health-
related quality of life associated with recombinant human
erythropoietin therapy for predialysis chronic renal disease
patients,” American Journal of Kidney Diseases, vol. 25, no. 4,
pp. 548–554, 1995.
[7] N. Clyne and T. Jogenstrand, “Eﬀect of erythropoietin treat-
ment on physical exercise capacity and on renal function in
predialytic uremic patients,” Nephron, vol. 60, no. 4, pp. 390–
396, 1992.
[8] V. S. Lim, R. L. DeGowin, D. Zavala et al., “Recombinant
human erythropoietin treatment in pre-dialysis patients.
A double-blind placebo-controlled trial,” Annals of Internal
Medicine, vol. 110, no. 2, pp. 108–114, 1989.
[9] T. B. Dru¨eke, K. U. Eckardt, U. Frei et al., “Does early anemia
correction prevent complications of chronic renal failure?”
Clinical Nephrology, vol. 51, no. 1, pp. 1–11, 1999.
[10] S. Nurko, “Anemia in chronic kidney disease: causes, diagno-
sis, treatment,” Cleveland Clinic Journal of Medicine, vol. 73,
no. 3, pp. 289–297, 2006.
10 Anemia
[11] A. Besarab and S. Soman, “Anemia management in chronic
heart failure: lessons learnt from chronic kidney disease,”
Kidney and Blood Pressure Research, vol. 28, no. 5-6, pp. 363–
371, 2006.
[12] M. A. Popovsky and B. J. Ransil, “Long-term impact of
recombinant human erythropoietin on transfusion support in
patients with chronic renal failure,” Immunohematology, vol.
12, no. 1, pp. 1–3, 1996.
[13] T. B. Dru¨eke, F. Locatelli, N. Clyne et al., “Normalization of
hemoglobin level in patients with chronic kidney disease and
anemia,” The New England Journal of Medicine, vol. 355, no.
20, pp. 2071–2084, 2006.
[14] A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia
with epoetin alfa in chronic kidney disease,” The New England
Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006.
[15] C. H. Chang, C. C. Chang, and S. S. Chiang, “Reduction
in erythropoietin doses by the use of chronic intravenous
iron supplementation in iron-replete hemodialysis patients,”
Clinical Nephrology, vol. 57, no. 2, pp. 136–141, 2002.
[16] S. Fishbane, G. L. Frei, and J. Maesaka, “Reduction in
recombinant human erythropoietin doses by the use of
chronic intravenous iron supplementation,” American Journal
of Kidney Diseases, vol. 26, no. 6, pp. 41–46, 1995.
[17] K. Miyashita, A. Tojo, K. Kimura et al., “Blood pressure
response to erythropoietin injection in hemodialysis and
predialysis patients,” Hypertension Research, vol. 27, no. 2, pp.
79–84, 2004.
[18] T. Ng, G. Marx, T. Littlewood, and I. Macdougall, “Recombi-
nant erythropoietin in clinical practice,” Postgraduate Medical
Journal, vol. 79, no. 933, pp. 367–376, 2003.
[19] Amgen Inc, Aranesp Prescribing information, 2007.
[20] US Food and Drug Administration, Postmarketing drug
safety information for patients and providers, Approved Risk
evaluation and Mitigation Strategies (REMS), 2010, http://
www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo-
rmationforPatientsandProviders/ucm111350.htm.
[21] D. W. Coyne, T. Kapoian, W. Suki et al., “Ferric gluconate is
highly eﬃcacious in anemic hemodialysis patients with high
serum ferritin and low transferrin saturation: results of the
dialysis Patients’ response to IV iron with elevated ferritin
(DRIVE) study,” Journal of the American Society of Nephrology,
vol. 18, no. 3, pp. 975–984, 2007.
[22] T. Kapoian, N. B. O’Mara, A. K. Singh et al., “Ferric gluconate
reduces epoetin requirements in hemodialysis patients with
elevated ferritin,” Journal of the American Society of Nephrol-
ogy, vol. 19, no. 2, pp. 372–379, 2008.
[23] National Kidney Foundation, “KDOQI clinical practice guide-
lines and clinical practice recommendations for anemia in
chronic kidney disease,” American Journal of Kidney Disease,
vol. 47, no. 5, supplement 3, pp. S11–S145, 2006.
[24] M. V. DeVita, S. Mittal, D. Frumkin, A. Kamran, S. Fishbane,
and M. F. Michelis, “Targeting higher ferritin concentra-
tions with intravenous iron dextran lowers erythropoietin
requirement in hemodialysis patients,” Clinical Nephrology,
vol. 60, no. 5, pp. 335–340, 2003.
[25] W. L. St Peter, G. T. Obrador, T. L. Roberts, and A. J. Collins,
“Trends in intravenous iron use among dialysis patients in
the United States (1994–2002),” American Journal of Kidney
Diseases, vol. 46, no. 4, pp. 650–660, 2005.
[26] J. W. R. Twisk, “Generalized Estimating Equations, Applied
Longitudinal Data Analysis for Epidemiology,” A practical
guide, pp. 55—98, 2003.
[27] M. J. Norusis, SPSS 16.0 Advanced Statistical Procedures Comp-
anion, Prentice Hall Inc, Upper Saddle River, NJ, USA, 2008.
[28] G. R. Bailie, G. Eisele, L. Liu et al., “Patterns of medication
use in the RRI-CKD study: focus on medications with
cardiovasculars eﬀects,” Nephrology Dialysis Transplantation,
vol. 20, pp. 1110–1115, 2005.
[29] R. S. Rasu, H. J. Manley, T. Crawford, and R. Balkrishnan,
“Undertreatment of anemia in patients with chronic kidney
disease in the United States: analysis of national outpatient
survey data,” Clinical Therapeutics, vol. 29, no. 7, pp. 1524–
1534, 2007.
[30] S. M. Payne, “Iron and virulence in Shigella,” Molecular
Microbiology, vol. 3, no. 9, pp. 1301–1306, 1989.
[31] S. M. Payne, “Iron and virulence in the family Enterobacte-
riaceae,” Critical Reviews in Microbiology, vol. 16, no. 2, pp.
81–111, 1988.
[32] M. L. Guerinot, “Microbial iron transport,” Annual Review of
Microbiology, vol. 48, pp. 743–772, 1994.
[33] S. I. Patruta, R. Edlinger, G. Sunder-Plassmann, and W. H.
Ho¨rl, “Neutrophil impairment associated with iron therapy in
hemodialysis patients with functional iron deficiency,” Journal
of the American Society of Nephrology, vol. 9, no. 4, pp. 655–
663, 1998.
[34] P. S. Lim, Y. H. Wei, Y. L. Yu, and B. Kho, “Enhanced oxidative
stress in haemodialysis patients receiving intravenous iron
therapy,” Nephrology Dialysis Transplantation, vol. 14, no. 11,
pp. 2680–2687, 1999.
[35] D. Tovbin, D. Mazor, M. Vorobiov, C. Chaimovitz, and N.
Meyerstein, “Induction of protein oxidation by intravenous
iron in hemodialysis patients: role of inflammation,” American
Journal of Kidney Diseases, vol. 40, no. 5, pp. 1005–1012, 2002.
[36] R. A. Zager, A. C. Johnson, S. Y. Hanson, and H. Wasse,
“Parenteral iron formulations: a comparative toxicologic
analysis and mechanisms of cell injury,” American Journal of
Kidney Diseases, vol. 40, no. 1, pp. 90–103, 2002.
[37] H. I. Feldman, J. Santanna,W. Guo et al., “Iron administration
and clinical outcomes in hemodialysis patients,” Journal of the
American Society of Nephrology, vol. 13, no. 3, pp. 734–744,
2002.
[38] H. I. Feldman, M. Joﬀe, B. Robinson et al., “Administration of
parenteral iron and mortality among hemodialysis patients,”
Journal of the American Society of Nephrology, vol. 15, no. 6,
pp. 1623–1632, 2004.
[39] R. E. Polk, C. Fox, A. Mahoney, J. Letcavage, and C.
MacDougall, “Measurement of adult antibacterial drug use in
130 US hospitals: comparison of defined daily dose and days
of therapy,” Clinical Infectious Diseases, vol. 44, no. 5, pp. 664–
670, 2007.
[40] M. Shetka, J. Pastor, and P. Phelps, “Evaluation of the
defined daily dose method for estimating antiinfective use
in a university hospital,” American Journal of Health-System
Pharmacy, vol. 62, no. 21, pp. 2288–2292, 2005.
[41] A. Muller, D. L. Monnet, D. Talon, T. He´non, and X. Bertrand,
“Discrepancies between prescribed daily doses and WHO
defined daily doses of antibacterials at a university hospital,”
British Journal of Clinical Pharmacology, vol. 61, no. 5, pp. 585–
591, 2006.
[42] A. L. Pakyz, C. MacDougall, M. Oinonen, and R. E. Polk,
“Trends in antibacterial use in US academic health centers:
2002 to 2006,” Archives of Internal Medicine, vol. 168, no. 20,
pp. 2254–2260, 2008.
[43] G. R. Bailie, C. A. Johnson, and N. A. Mason, “Parenteral iron
use in the management of anemia in end-stage renal disease
patients,” American Journal of Kidney Diseases, vol. 35, no. 1,
pp. 1–12, 2000.
Anemia 11
[44] J. D. Robbins, J. J. Kim, G. Zdon, W. W. Chan, and J. Jones,
“Resource use and patient care associated with chronic kidney
disease in a managed care setting,” Journal of Managed Care
Pharmacy, vol. 9, no. 3, pp. 238–247, 2003.
[45] R. John, M. Webb, A. Young, and P. E. Stevens, “Unreferred
chronic kidney disease: a longitudinal study,” American Jour-
nal of Kidney Diseases, vol. 43, no. 5, pp. 825–835, 2004.
[46] C. F. Wong, M. McCarthy, M. L. P. Howse, and P. S. Williams,
“Factors aﬀecting survival in advanced chronic kidney disease
patients who choose not to receive dialysis,” Renal Failure, vol.
29, no. 6, pp. 653–659, 2007.
[47] I. H. Khan, G. R. Catto, N. Edward, L. W. Fleming, I. S.
Henderson, and A. M. MacLeod, “Influence of coexisting
disease on survival on renal-replacement therapy,” The Lancet,
vol. 341, no. 8842, pp. 415–418, 1993.
[48] S. J. Davies, L. Phillips, P. F. Naish, and G. I. Russell,
“Quantifying comorbidity in peritoneal dialysis patients and
its relationship to other predictors of survival,” Nephrology
Dialysis Transplantation, vol. 17, no. 6, pp. 1085–1092, 2002.
[49] M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie,
“A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation,” Journal of
Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987.
[50] J. G. van Manen, P. C. van Dijk, V. S. Stel et al., “Confounding
eﬀect of comorbidity in survival studies in patients on renal
replacement therapy,” Nephrology Dialysis Transplantation,
vol. 22, no. 1, pp. 187–195, 2007.
[51] Y. Shen, “Applying the 3M all patient refined diagnosis related
groups grouper to measure inpatient severity in the VA,”
Medical Care, vol. 41, no. 6, pp. II103–II110, 2003.
[52] L. I. Iezzoni, M. Shwartz, A. S. Ash, and Y. D. Mackiernan,
“Does severity explain diﬀerences in hospital length of stay
for pneumonia patients?” Journal of Health Services Research
& Policy, vol. 1, no. 2, pp. 65–76, 1996.
[53] M. Shwartz, L. I. Iezzoni, A. S. Ash, and Y. D. Mackiernan, “Do
severity measures explain diﬀerences in length of hospital stay?
The case of hip fracture,” Health Services Research, vol. 31, no.
4, pp. 365–385, 1996.
[54] L. Jeﬀeries, M. E. Smith, D. Magee, P. Wallace, andM. Horgan,
“A team approach to decrease wasted blood products,” Labo-
ratory Medicine, vol. 27, no. 12, pp. 833–839, 1996.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
